These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 31724750)
1. Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting. Bertoni S; Machness A; Tiboni M; Bártolo R; Santos HA Biopolymers; 2020 Jan; 111(1):e23336. PubMed ID: 31724750 [TBL] [Abstract][Full Text] [Related]
2. Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy. Long J; Liang X; Ao Z; Tang X; Li C; Yan K; Yu X; Wan Y; Li Y; Li C; Zhou M Acta Biomater; 2024 Oct; 188():27-47. PubMed ID: 39265673 [TBL] [Abstract][Full Text] [Related]
3. Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives. Chen M; Lan H; Jin K; Chen Y Drug Deliv; 2023 Dec; 30(1):2219427. PubMed ID: 37288799 [TBL] [Abstract][Full Text] [Related]
4. [Reactive oxygen species stimuli-responsive nanocarriers]. Zhou W; Yang K; Zhao B; Zhang L; Zhang Y Se Pu; 2021 Feb; 39(2):118-124. PubMed ID: 34227343 [TBL] [Abstract][Full Text] [Related]
5. Biocompatible reactive oxygen species (ROS)-responsive nanoparticles as superior drug delivery vehicles. Zhang D; Wei Y; Chen K; Zhang X; Xu X; Shi Q; Han S; Chen X; Gong H; Li X; Zhang J Adv Healthc Mater; 2015 Jan; 4(1):69-76. PubMed ID: 25147049 [TBL] [Abstract][Full Text] [Related]
6. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease. Li S; Xie A; Li H; Zou X; Zhang Q J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913 [TBL] [Abstract][Full Text] [Related]
7. Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges. Nunes R; Neves JD; Sarmento B Nanomedicine (Lond); 2019 Oct; 14(19):2631-2644. PubMed ID: 31612773 [TBL] [Abstract][Full Text] [Related]
8. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Hua S; Marks E; Schneider JJ; Keely S Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453 [TBL] [Abstract][Full Text] [Related]
9. Nanoparticle targeting to inflamed tissues of the gastrointestinal tract. Moulari B; Beduneau A; Pellequer Y; Lamprecht A Curr Drug Deliv; 2013 Feb; 10(1):9-17. PubMed ID: 22998041 [TBL] [Abstract][Full Text] [Related]
10. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy. Zhao P; Xia X; Xu X; Leung KKC; Rai A; Deng Y; Yang B; Lai H; Peng X; Shi P; Zhang H; Chiu PWY; Bian L Nat Commun; 2021 Dec; 12(1):7162. PubMed ID: 34887414 [TBL] [Abstract][Full Text] [Related]
11. Stimuli-responsive polymer-based nanosystems for cardiovascular disease theranostics. Liu Y; Li C; Yang X; Yang B; Fu Q Biomater Sci; 2024 Jul; 12(15):3805-3825. PubMed ID: 38967109 [TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species-responsive nanoplatforms for nucleic acid-based gene therapy of cancer and inflammatory diseases. Zhu D; Chen W; Lin W; Li Y; Liu X Biomed Mater; 2021 Jun; 16(4):. PubMed ID: 34116517 [TBL] [Abstract][Full Text] [Related]
14. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis. Dou Y; Chen Y; Zhang X; Xu X; Chen Y; Guo J; Zhang D; Wang R; Li X; Zhang J Biomaterials; 2017 Oct; 143():93-108. PubMed ID: 28778000 [TBL] [Abstract][Full Text] [Related]
15. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Hunter AC; Elsom J; Wibroe PP; Moghimi SM Nanomedicine; 2012 Sep; 8 Suppl 1():S5-20. PubMed ID: 22846372 [TBL] [Abstract][Full Text] [Related]
16. Internal stimuli-responsive nanocarriers for drug delivery: Design strategies and applications. Liu M; Du H; Zhang W; Zhai G Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():1267-1280. PubMed ID: 27987683 [TBL] [Abstract][Full Text] [Related]
17. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine. Li W; Li Y; Liu Z; Kerdsakundee N; Zhang M; Zhang F; Liu X; Bauleth-Ramos T; Lian W; Mäkilä E; Kemell M; Ding Y; Sarmento B; Wiwattanapatapee R; Salonen J; Zhang H; Hirvonen JT; Liu D; Deng X; Santos HA Biomaterials; 2018 Dec; 185():322-332. PubMed ID: 30267958 [TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives. Yang C; Merlin D Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785 [TBL] [Abstract][Full Text] [Related]
19. Reactive oxygen species-scavenging nanomedicines for the treatment of oxidative stress injuries. Yoshitomi T; Nagasaki Y Adv Healthc Mater; 2014 Aug; 3(8):1149-61. PubMed ID: 24482427 [TBL] [Abstract][Full Text] [Related]
20. Stimuli-responsive Carriers for Controlled Intracellular Drug Release. Sheng Y; Hu J; Shi J; Lee LJ Curr Med Chem; 2019; 26(13):2377-2388. PubMed ID: 28875840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]